Antisense Oligonucleotides Silencing MGMT to Restore Temozolomide Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glioblastoma multiforme (GBM) tumors are resistant to current treatments due to the presence of cancer stem cells and the enzyme 6-O-methylguanine DNA methyltransferase (MGMT), leading to poor prognosis and tumor recurrence, as existing treatments like temozolomide become ineffective over time.
Innovation Solution
The use of antisense oligonucleotides that target and reduce the expression levels of the huntingtin protein and MGMT in glioma cells, sensitizing them to anti-cancer treatments by decreasing their resistance mechanisms, thereby enhancing the effectiveness of DNA-damaging agents like temozolomide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If temozolomide is used as anti-cancer treatment, then tumor growth is slowed initially, but tumor cells develop resistance over time due to MGMT enzyme expression
Solution Approach 1:
The patent applies preliminary action by using antisense oligonucleotides to pre-silence the MGMT gene expression in tumor cells before administering temozolomide. This preliminary molecular modification prevents the development of resistance mechanisms, allowing the DNA-alkylating agent to maintain its effectiveness throughout treatment. The ASO treatment is given prior to or concurrent with chemotherapy to establish resistant-cell-free conditions in advance.
2Reliability
If cancer stem cells are present in GBM tumors, then tumor recurrence occurs, but complete surgical removal is impossible due to rapid proliferation and invasion
Solution Approach 1:
The patent applies the extraction principle by specifically targeting and eliminating cancer stem cells through MGMT gene silencing. The antisense oligonucleotides selectively reduce MGMT expression in stem cell populations, which are the primary drivers of recurrence. This molecular extraction approach removes the problematic stem cell component without requiring complete surgical removal of all tumor tissue.
3Reliability
If MGMT enzyme is expressed in tumor cells, then resistance to temozolomide develops, but no alternative treatment exists
Solution Approach 1:
The patent introduces an intermediary substance - the antisense oligonucleotide - that mediates between the temozolomide treatment and the MGMT enzyme. The ASO binds to MGMT mRNA and prevents translation, effectively blocking the enzyme's protective function. This intermediary molecular mechanism restores temozolomide sensitivity without requiring alternative chemotherapy agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reduction in huntingtin and MGMT protein levels in glioma cells increases the sensitivity of these cells to anti-cancer treatments, reducing the lethal dose required for temozolomide by at least 30-45% and preventing tumor recurrence by making the cells more susceptible to DNA damage.
Implementation Method 1
The mRNA is then degraded by RNAse H and is therefore not translated into protein
Implementation Method 2
The mRNA is then degraded by RNAse H
Implementation Method 3
The mRNA is then degraded by RNAse H and is therefore not translated into protein
Implementation Method 4
The mRNA is then degraded by RNAse H
Implementation Method 5
The TMZ is a DNA alkylating agent that adds a methyl group at the N-7 or O-6 position of guanine and at the N-3 position of adenine
Data Source
AI summary
An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.